Lv71
3700 积分 2022-01-11 加入
Challenges and countermeasures of Investigator-Initiated Trial of oncology
4小时前
求助中
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
1个月前
已完结
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
2个月前
已完结
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
2个月前
已完结
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2个月前
已完结
Clinical practice guideline of BRCA1/2 testing for patients with breast cancer: Chinese Society of Breast Surgery （CSBrS） practice guideline 2021.
5个月前
已完结
复发/转移性头颈部鳞癌免疫检查点抑制剂治疗专家共识
8个月前
已完结
局部晚期头颈部鳞癌治疗进展
8个月前
已完结
皖公网安备34019202002308
